

Serial No.: 09447,226

News

Meetings & Education

▶ Calendar of Events

▶ Annual Meeting

▼ Abstracts

Search Abstracts

▶ Symposia & Workshops

▶ Virtual Meetings

▶ CME

Policy & Practice

Publications

Practice Guidelines

Career Development



VISIT OTHER ASCO SITES

- ▶ Journal of Clinical Oncology
- ▶ ASCO Foundation
- ▶ People Living With Cancer
- ▶ ASCO MD

BECOME A MEMBER

ASCO MEMBERS

Membership Directory, Web/Tech Review,
ASCO MDusername

password

LOGIN

[Home](#) > [Meetings & Education](#) > [Abstracts](#) >Applicant: Abbott Laboratories
Examiner: Lukton, David
Exhibit 4(a)**Antiangiogenic thrombospondin-I peptides result in regression of naturally occurring cancers in pet dogs.**

Year: 2002

[Printable Version](#)

Abstract No: 85

Category: Other Novel Therapies

Author(s):

Chand Khanna, Tony Rusk, Fortuna Haviv, Jack Henkin, Animal Cancer Institute, LLC, Columbia, MD; Abbott Laboratories, Abbott Park, IL.

Abstract:

Thrombospondin-1 (TSP-1) is a natural antiangiogenic protein that enhances apoptosis in activated endothelial cells (EC). D-amino acid substituted peptides within the TSP-1(Mal II) sequence inhibit EC function. A related antiangiogenic nonapeptide (ABT526) was found to slow tumor growth in syngeneic and xenograft mouse models. To examine the safety and efficacy of ABT526 antiangiogenic therapy a prospective pre-clinical trial in pet dogs with naturally occurring cancers was undertaken. Eligible cases had histologically confirmed measurable cancers, no cancer therapy within 21 days and no concurrent cancer therapy. The first 26 cases received 12.5 mg BID, SC; subsequent cases received 0.5 mg/kg BID, SC. Treatment was continued until significant progressive disease (SPD). Endpoints included adverse effects, significant disease stabilization and objective responses (PR >50%; CR 100% response) in measurable lesions. Seventy-four cases (carcinomas, lymphomas, sarcomas and others) were entered for study. Over 95% had failed conventional treatments prior to ABT526 monotherapy. Fifty-six dogs received at least 30 days of therapy before SPD (evaluable cases). Treatment was not associated with observable toxicity in any animal, and no disturbance of wound healing was seen in four cases requiring surgery. Unexpected disease stabilization and objective responses were seen in 11/56 and 8/56 evaluable cases, respectively. Relapse after durable objective responses were seen in 8/8 cases (see table). Results suggest that ABT526 therapy is well-tolerated, effective, and associated with regression of measurable lesions in naturally occurring cancers. A randomized trial of ABT-526 plus chemotherapy alone in canine NH lymphoma is underway.

Objective responders with ABT526 antiangiogenic therapy

Histology	Clinical Stage	Response
Nasal Carcinoma	T3bN0M0	CR
Cutaneous Lymphoma	Generalized	CR
Nasal Carcinoma	T3bN1M0	PR
NH Lymphoma	IIIB	PR
Soft Tissue	T2bN2N3bM1(lung)	PR